analyze 249 patients, including types of non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial carcinoma, who have received second-line therapy with or without PD-1/PD-L1 inhibitors, and demonstrate that 69 patients who have recently taken antibiotics after receiving ICIs treatment, progression-free survival (PFS) and overall survival (OS) are significantly shortened. The gene discussed is CD274; the disease is non-small cell lung carcinoma.